The Global $43.42bn Market for Anticoagulants (2018-2025): Analysis by Drug Class, Route of Administration and Application - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “Anticoagulants Market by Drug Class, Route of Administration, and Application - Global Opportunity Analysis and Industry Forecast, 2018-2025” report has been added to ResearchAndMarkets.com’s offering.
According to the report, the market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025.
The global anticoagulants market is anticipated to show significant market growth during the forecast period, owing to increase in prevalence of ischaemic heart disease and venous thromboembolism (VTE) and awareness of novel oral anticoagulants (NOACs).
In addition, increasing number of geriatric population and growing incidence of obese population is expected to further increase the demand for anticoagulants throughout the forecast period.
On the other side, very high cost of NOACs is expected to negatively affect the growth of the anticoagulants market.
Key FindingsAs per the drug class, the NOACs segment is expected to show the fastest market growth and grow at a CAGR of 8% from 2018 to 2025. On the basis of the route of administration, the oral anticoagulant segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. By application, the deep vein thrombosis (DVT) segment is expected to exhibit the fastest growth at a CAGR of 8.4% from 2018 to 2025. Region-wise, the Asia-Pacific region is expected to experience growth at the highest rate, registering a CAGR of 9.2% during the forecast period.
Key Topics Covered
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Anticoagulants Market, by Drug Class
Chapter 5: Anticoagulants Market, by Route of Administration
Chapter 6: Anticoagulants Market, by Application
Chapter 7: Anticoagulants Market, by Region
Chapter 8: Company ProfilesAspen Holdings Bayer AG Boehringer Ingelheim Pharma GmbH & Co. KG Bristol-Myers Squibb Company Daiichi Sankyo Co. Ltd. GlaxoSmithKline plc Johnson & Johnson (Janssen Pharmaceuticals Inc.) Pfizer Inc. Portola Pharmaceuticals Inc. Sanofi
For more information about this report visit https://www.researchandmarkets.com/research/ws5fbj/the_global_43?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180918006087/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/18/2018 04:24 PM/DISC: 09/18/2018 04:24 PM